Clinical Trial Update: A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas [Phase 1]

View source ↗

Summary

Phase I study of alisertib combined with R-EPOCH for myc-positive aggressive B-cell lymphomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Alisertib (alisertib)
• R-EPOCH regimen (rituximab-etoposide-prednisone-vincristine-doxorubicin-cyclophosphamide regimen)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 | Status: TERMINATED